Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

  1. Mok, T.S.
  2. Cheng, Y.
  3. Zhou, X.
  4. Lee, K.H.
  5. Nakagawa, K.
  6. Niho, S.
  7. Chawla, A.
  8. Rosell, R.
  9. Corral, J.
  10. Migliorino, M.R.
  11. Pluzanski, A.
  12. Noonan, K.
  13. Tang, Y.
  14. Pastel, M.
  15. Wilner, K.D.
  16. Wu, Y.-L.
Aldizkaria:
Drugs

ISSN: 1179-1950,  0012-6667

Argitalpen urtea: 2021

Alea: 81

Zenbakia: 2

Orrialdeak: 257-266

Mota: Artikulua

DOI: 10.1007/S40265-020-01441-6 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus